Advanced search
Start date

Characterization of recombinant antigens and immune response of a new rabies vaccine candidate

Grant number: 18/10538-1
Support type:Regular Research Grants
Duration: October 01, 2018 - September 30, 2020
Field of knowledge:Biological Sciences - Microbiology
Principal Investigator:Renato Mancini Astray
Grantee:Renato Mancini Astray
Home Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
Assoc. researchers:Elisabeth de Fatima Pires Augusto ; Helio Langoni ; Soraia Attie Calil Jorge


Rabies control is one of the global health challenges. While under developed countries are still implementing basic prevention activities against human and animal rabies, developed countries which have already controlled urban rabies are challenged for its control in sylvatic areas. Currently available vaccines are generally effective but present high production costs, biosafety risks and short term immune protection. The possibility of obtaining a recombinant vaccine against rabies has guided our studies for years. An effective vaccine preparation that combines high immune response mediated by neutralizing antibodies, with a good level of cellular immune response, can lead to the proposition of a new and more powerful anti-rabies vaccine. Several technologies may give rise to this preparation. The approaches considered in this project involve the production of the vaccine antigen, the rabies Lyssavirus glycoprotein (GPV), by S2 insect cells or in the VLP form through the baculovirus-Sf9 system. The production of GPV by these systems already has a good level of knowledge by our group. Our focus at this moment is the characterization of purified GPV according to biochemical aspects of composition and structure and according to immunological aspects, through the analysis of epitopes and the immune response in mice. The project also covers the study of the immune response in the context of the addition of modern adjuvants to vaccine preparations. As a result of this project, an animal vaccine candidate, based on adjuvant-associated recombinant protein, is expected to be proposed. (AU)